Thus, inhibition of ID1 signaling in JAK2-V617F mediated MPN might contribute to a positive clinical outcome, as ID1 maintains the self-renewal capacity of myeloid progenitor cells [33]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.